Key result
ALDH2 variants link alcohol consumption to ~2-fold higher odds of subclinical cardiac dysfunction.
Why the study?
Current alcohol guidelines do not account for genetic susceptibility, and the ALDH2*2 variant affecting 30-40% of East Asians may amplify alcohol-related cardiac injury at consumption levels considered safe by international standards.
Does the ALDH2*2 genetic variant amplify alcohol-related subclinical cardiac dysfunction at low levels of daily alcohol consumption in a Northern Taiwan cohort?
Cohort (n=1,871)
Yes
Does the ALDH2*2 genetic variant amplify alcohol-related subclinical cardiac dysfunction at low levels of daily alcohol consumption in a Northern Taiwan cohort?
Subclinical cardiac dysfunction occurs at alcohol consumption levels as low as 6 g/day—well below current international guideline thresholds—and is significantly amplified in carriers of the ALDH2*2 genetic variant.
ALDH2-alcohol interaction may worsen LA strain in variant carriers; leaves open genotype-specific intake thresholds pending prospective trials.
Background/Introduction Current alcohol guidelines do not account for genetic susceptibility. The ALDH2*2 variant, affecting 30-40% of East Asians, impairs acetaldehyde metabolism and may amplify alcohol-related cardiac injury at consumption levels considered safe by international standards. Purpose To investigate gene-alcohol interactions in subclinical cardiac dysfunction using advanced strain imaging and determine optimal alcohol thresholds for genetically susceptible individuals. Methods We studied 1,871 participants from Northern Taiwan cohorts (967 genotyped). Cardiac function was evaluated using speckle-tracking echocardiography to measure left atrial (LA) and left ventricular (LV) strain. ALDH2 genotype (rs671) and daily alcohol consumption were assessed. Restricted cubic spline (RCS) regression was used to evaluate non-linear dose-response relationships. ROC analysis determined optimal alcohol thresholds for predicting subclinical cardiac dysfunction defined by strain cut-offs (LA <23%, LV ≤18%). Gene-alcohol interactions and sex-specific effects were analysed using regression models. Results RCS analysis revealed progressive, non-linear deterioration in both chambers even at low alcohol doses. Continuous analysis demonstrated dose-dependent deterioration (LA: β = -0.035 % per g/day; LV: β = -0.013 % per g/day, p < 0.001). ALDH2 variants significantly amplified alcohol's effects through gene-alcohol interactions (LA: β = -0.063, p = 0.001; LV: β = -0.023, p < 0.001). ROC analysis identified 6 g/day as the optimal cut-off for predicting dysfunction, far below international guidelines (10-48 g/day). Variant carriers showed 2-2.5-fold higher dysfunction odds despite consuming less alcohol (7.6 vs 16.7 g/day, p<0.001). Males demonstrated vulnerability to both chambers, whilst females showed predominantly ventricular susceptibility. Additional interactions involving ADH1B, ADH1C, and CYP2E1 polymorphisms further amplified alcohol-related cardiac dysfunction. Conclusions Subclinical cardiac dysfunction occurs at 6 g/day, substantially below current guideline thresholds. ALDH2 genetic polymorphisms critically modify alcohol-related cardiac injury through gene-alcohol interactions. These findings support precision medicine approaches integrating genetic risk stratification and sensitive cardiac imaging to guide individualised alcohol recommendations.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) conducted a cohort in Subclinical alcohol-related cardiac dysfunction (n=1,871). ALDH2 variant (rs671) and daily alcohol consumption vs. Non-carriers / lower or no alcohol consumption was evaluated on Subclinical cardiac dysfunction defined by speckle-tracking echocardiography strain cut-offs (left atrial strain <23%, left ventricular strain ≤18%) (LA interaction β = -0.063; LV interaction β = -0.023 (2-2.5-fold higher dysfunction odds in variant carriers), p=<0.001). ALDH2 variants amplified alcohol-related cardiac strain deterioration (LA β=-0.063, p=0.001; LV β=-0.023, p<0.001), conferring 2-2.5-fold higher dysfunction odds with a 6 g/day optimal cut-off.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: